Defining the palliative care population
The World Health Organization defines palliative care as 'an approach that improves the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual' [1] . Palliative care was founded to give greater dignity at the end of life by changing the focus from purely a biomedical approach to care that aimed to relieve suffering by combining scientific knowledge with care, support and choice; recognizing these patients were often marginalized in health care systems [2] .
Importantly, palliative care may be provided early in the course of illness, in conjunction with other interventions aimed to offer survival benefit, such as chemotherapy, dialysis and other disease-specific treatments [1] . The desired outcomes of clinical interventions will vary depending on individual circumstances, influenced by a range of factors including illness trajectory [3] , available therapies, and patient preference and goals of care. Assessment of any palliative intervention needs to encompass a combination of clinical outcomes which may include survival benefit, functional goals, symptom control, psychological and spiritual wellbeing, and enabling patient choice (e.g. care in place of choice, achieving personal goals) [4] . These principles apply when evaluating the role of cannabinoids in palliative care, where it is important to understand the net clinical benefits, that is how both the benefits and harms contribute to the outcome(s) of interest [5] .
Public opinion is undergoing a dramatic shift, with polls showing that the substantial majority support legalization for medicinal use [6] , and this is particularly true about access to those who are terminally ill. It is also well established that patients seek medicinal cannabis for symptom relief, with a survey of Australian cancer patients showing that 26% reported prior medicinal cannabis use; commonly for pain, appetite loss, psychological symptoms, insomnia and nausea [7] . Similarly, a study from a US Cancer Center in a state where both medicinal and recreational use is legal, found a quarter of participants reported medicinal use most commonly for physical symptoms such as pain, nausea, appetite, but also for stress management, coping and improving mood and sleep [8] . In palliative care patients, there is also a range of views on the relative merits of botanical versus pharmaceutical cannabinoids.
Guiding principles of palliative symptom management
There are several guiding principles that should underpin the pharmacological treatment of symptoms in the palliative care setting, namely: i careful assessment, including consideration of the pathophysiological cause(s); ii for first line therapy, consider the number needed to benefit and number needed to harm from most recent evidence [5] ; iii consider the role of non-pharmacological therapies; iv regular reassessment of both benefits and harms; v awareness of off-label (unapproved dose, route and/or indication) and unregistered medicines [9] with appropriate shared decision-making and consent from the patient; vi consider pharmacokinetics (renal failure, hepatic impairment, weight loss [10] ); vii consider pharmacodynamics (e.g. co-existing cognitive impairment); viii consider drug-drug interactions (e.g. other psychoactive medications such as opioids, benzodiazepines, antidepressants, anticonvulsants, and antipsychotics) [11] .
Symptom areas with potential role for cannabinoids
There are several symptom areas where cannabinoids have been evaluated [12] .
Nausea
Nausea in palliative care patients is often multifactorial with heterogeneous biological mechanisms that can vary depending on whether the person has a malignant or non-malignant palliative diagnosis [13] . Nausea and vomiting can co-occur or be isolated symptoms, and treatment needs to consider reversible causes and be tailored to the individual clinical situation [13] . First-line therapy may include prokinetic agents, dopamine receptor antagonists, and H 1 receptor antagonists; and studies are need to determine the role of cannabinoids in comparison or in conjunction with these, and in those refractory to first-line treatments [13] . The evaluation of cannabinoids has been in chemotherapy-induced nausea and vomiting (CINV), with a recent systematic review finding no difference between prochlorperazine and cannabinoids for nausea and vomiting; and comparisons with other antiemetics had insufficient data to draw a conclusion [14] . In CINV, comparisons are needed with highly effective 5-hydroxytryptamine type 3 (5-HT 3 ) receptor antagonists, neurokinin-1 receptor antagonists and olanzapine [15] .
Cancer pain
Preclinical data supports the potential role of cannabinoids in pain modulation, including in cancer pain; however, this has not been supported by compelling clinical evidence in the trials to date [16] . Despite promising earlier studies [17, 18] , three recent Phase 3 studies of nabiximols in people with advanced cancer with pain that is unrelieved despite optimized opioids failed to demonstrate benefit in self-reported average numerical rating scales for pain (when considered as percent improvement or mean change from baseline to end of treatment) [19, 20] .
Anorexia
Current pharmacological therapies for anorexia include progestins [21] and corticosteroids [22] , which provide limited and short-term improvements in appetite, weight or food enjoyment; and use is often limited by side effects. Delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis, has effects in the hypothalamus and on dopamine transmission that mediate beneficial effects on appetite. A synthetic formulation of THC (dronabinol) has FDA approval for the treatment of anorexia associated with weight loss in HIV-AIDS at a time that it was a universally terminal illness. However, the studies that have been performed that underpinned this were of short duration, in small numbers of patients, focused on short-term measures of efficacy, and have not explored longer term benefits in the current environment of effective antiretroviral therapy [23] . There is some evidence for the positive effects of THC with two Phase 2 studies demonstrating impact on appetite and improved food taste in people with cancer [24] . However, two Phase 3 studies failed to show benefit [25, 26] . There are two emerging therapies for cancer-related cachexia, enobosarm [27] and anamorelin [28] which will warrant comparison.
Other impacts
Effects of mild euphoria and sense of wellbeing may impact on existential and spiritual wellbeing. People facing a terminal illness may use cannabis not only to find relief of physical symptoms such as pain or nausea, but also to enhance wellbeing and restore a sense of 'normality' through euphoria and enhanced sensorium and awareness [29] .
Practical considerations
Consideration for continuity of therapy needs to be considered for people who are near the end of life, as the clinical scenarios where medications can no longer be swallowed, or cannot be self-administered, are common. Medication administration is often a role which is taken by informal carers and health providers both in community, residential aged care/nursing home and acute care/inpatient settings.
Consequently, the training and education of professional and informal caregivers needs to be considered. In particular, if the medicinal cannabis product is not a registered pharmaceutical product, an accurate source of information about the product (e.g. content, dose and route of administration) is essential. Lack of parenteral formulations also pose limitations for the care of people who are imminently dying, where oral vaporized or oromucosal formulations are no longer possible. Equally, continuity when patients transition between care settings needs to be considered.
Conclusions
The management of symptoms in palliative care patients requires meticulous clinical assessment and tailored pharmacological approaches, underpinned by both pathophysiological understanding and the evidence base. Ideally, exploration of medicinal cannabinoids should occur within a clinical trial to accelerate the evidence base to inform practice. In people with refractory symptoms, the consideration of unregistered products or off-label prescribing should be guided by the potential influences of pharmacokinetic, pharmacodynamic and drug-drug interactions, supported by an informed discussion with the patient, and regular review of net clinical benefit.
